Safety and efficacy of parsaclisib in combination with rituximab, bendamustine plus rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL-112)
Por:
Sancho, JM, Abrisqueta, P, Kumar, A, Cordoba, R, Tani, M, Langmuir, P, Rappold, E, Liu, T and Lopez-Guillermo, A
Publicada:
6 jun 2024
Ahead of Print:
1 abr 2024
Resumen:
Parsaclisib, a potent and highly selective phosphoinositide 3-kinase delta inhibitor, has shown clinical activity in relapsed/refractory (R/R) B-cell lymphoma. The phase 1 CITADEL-112 (NCT03424122) study assessed safety and efficacy of parsaclisib in combination with investigator choice standard of care (SOC; rituximab [Treatment A], rituximab plus bendamustine [Treatment B], or ibrutinib [Treatment C]) in 50 patients with R/R B-cell lymphoma. The most common treatment-emergent adverse events included neutropenia (62.5%, 50.0%, and 50.0% of patients in Treatments A, B, and C, respectively); diarrhea (37.5%) and anemia (31.3%) in Treatment A; abdominal pain, asthenia, diarrhea, and nausea (each 33.3%) in Treatment B; and increased alanine and aspartate aminotransferase (each 37.5%) in Treatment C. Objective responses were observed in 13 patients (81.3%) in Treatment A, 10 (55.6%) in Treatment B, and 8 (50.0%) in Treatment C. Parsaclisib combined with SOC therapies had an expected safety profile and promising efficacy in patients with R/R B-cell lymphomas.
Filiaciones:
:
Inst Catala Oncol, Hosp Germans Trias & Pujol, Dept Clin Hematol, IJC, Barcelona, Spain
Abrisqueta, P:
Vall dHebron Inst Oncol VHIO, Hosp Univ Vall dHebron, Dept Hematol, Barcelona, Spain
Kumar, A:
Univ Arizona, Tucson, AZ USA
Cordoba, R:
Fdn Jimenez Diaz Univ Hosp, Hlth Res Inst IIS FJD, Dept Hematol, Lymphoma Unit, Madrid, Spain
Tani, M:
Santa Maria Croci Hosp, Haematol Unit, Ravenna, Italy
Langmuir, P:
Incyte Corp, Wilmington, DE USA
Rappold, E:
Incyte Corp, Wilmington, DE USA
Liu, T:
Incyte Corp, Wilmington, DE USA
Lopez-Guillermo, A:
Clin Barcelona, Barcelona, Spain
hybrid
|